Introduction to corrigendum to ‘Level of MFAP4 in ascites independently predicts 1-year transplant-free survival in patients with cirrhosis’ [JHEP Reports 3 (2021) 100287]

It has come to our attention that the units for both serum MFAP4 and ascites MFAP4 were erroneously reported as U/L in our article rather than the correct units, U/ml. Please see the corrected version of the article here. This error has also been corrected in the online supplementary file. We apologise for this error and any inconvenience caused. Corrigendum to ‘Level of MFAP4 in ascites independently predicts 1-year transplant-free survival in patients with cirrhosis’ [JHEP Reports 3 (2021) 100287]JHEP ReportsVol. 3Issue 5PreviewPrognostic models of cirrhosis underestimate disease severity for patients with cirrhosis and ascites. Microfibrillar-associated protein 4 (MFAP4) is an extracellular matrix protein linked to hepatic neoangiogenesis and fibrogenesis. We investigated ascites MFAP4 as a predictor of transplant-free survival in patients with cirrhosis and ascites. Full-Text PDF Open AccessLevel of MFAP4 in ascites independently predicts 1-year transplant-free survival in patients with cirrhosisJHEP ReportsVol. 3Issue 3PreviewPrognostic models of cirrhosis underestimate disease severity for patients with cirrhosis and ascites. Microfibrillar-associated protein 4 (MFAP4) is an extracellular matrix protein linked to hepatic neoangiogenesis and fibrogenesis. We investigated ascites MFAP4 as a predictor of transplant-free survival in patients with cirrhosis and ascites. Full-Text PDF Open Access